Literature DB >> 12033778

RSV-induced immunopathology: dynamic interplay between the virus and host immune response.

Steven M Varga1, Thomas J Braciale.   

Abstract

Mesh：

Year:  2002        PMID： 12033778     DOI： 10.1006/viro.2002.1382

Source DB:  PubMed          Journal:  Virology        ISSN： 0042-6822            Impact factor:   3.616


× No keyword cloud information.
  19 in total

1.  Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P.

Authors:  Lia M Haynes; Les P Jones; Albert Barskey; Larry J Anderson; Ralph A Tripp
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

2.  Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector.

Authors:  Luis Martinez-Sobrido; Negin Gitiban; Ana Fernandez-Sesma; Jerome Cros; Sara E Mertz; Nancy A Jewell; Sue Hammond; Emilio Flano; Russell K Durbin; Adolfo García-Sastre; Joan E Durbin
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  T Cell receptor clonotype influences epitope hierarchy in the CD8+ T cell response to respiratory syncytial virus infection.

Authors:  Padma Billam; Kathryn L Bonaparte; Jie Liu; Tracy J Ruckwardt; Man Chen; Alex B Ryder; Rui Wang; Pradyot Dash; Paul G Thomas; Barney S Graham
Journal:  J Biol Chem       Date:  2010-11-30       Impact factor: 5.157

4.  RSV-specific anti-viral immunity is disrupted by chronic ethanol consumption.

Authors:  Kristi J Warren; Samantha M Simet; Jacqueline A Pavlik; Jane M DeVasure; Joseph H Sisson; Jill A Poole; Todd A Wyatt
Journal:  Alcohol       Date:  2016-08-25       Impact factor: 2.405

5.  Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice.

Authors:  Kate L Stokes; Michael H Chi; Kaori Sakamoto; Dawn C Newcomb; Michael G Currier; Matthew M Huckabee; Sujin Lee; Kasia Goleniewska; Carla Pretto; John V Williams; Anne Hotard; Taylor P Sherrill; R Stokes Peebles; Martin L Moore
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

6.  Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model.

Authors:  Asunción Mejías; Susana Chávez-Bueno; Ana María Ríos; Jesús Saavedra-Lozano; Mónica Fonseca Aten; Jeanine Hatfield; Payal Kapur; Ana María Gómez; Hasan S Jafri; Octavio Ramilo
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

7.  Expression of CTLA-4 (CD152) in peripheral blood T cells of children with influenza virus infection including encephalopathy in comparison with respiratory syncytial virus infection.

Authors:  H Ayukawa; T Matsubara; M Kaneko; M Hasegawa; T Ichiyama; S Furukawa
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

8.  Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice.

Authors:  Congrong Miao; Gertrud U Radu; Hayat Caidi; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  J Gen Virol       Date:  2009-03-04       Impact factor: 3.891

9.  Characterization of respiratory syncytial virus M- and M2-specific CD4 T cells in a murine model.

Authors:  Jie Liu; Tracy J Ruckwardt; Man Chen; Teresa R Johnson; Barney S Graham
Journal:  J Virol       Date:  2009-03-04       Impact factor: 5.103

10.  Respiratory syncytial virus synergizes with Th2 cytokines to induce optimal levels of TARC/CCL17.

Authors:  Martha M Monick; Linda S Powers; Ihab Hassan; Dayna Groskreutz; Timur O Yarovinsky; Christopher W Barrett; Elaine M Castilow; Delia Tifrea; Steven M Varga; Gary W Hunninghake
Journal:  J Immunol       Date:  2007-08-01       Impact factor: 5.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.